Papers
7
Total Citations
202
H-Index
6
About
Andreas du Bois is a leading figure in gynecologic oncology, with a research focus on borderline ovarian tumors (BOT) and the clinical application of homologous recombination deficiency (HRD) as a biomarker in ovarian cancer. His major contributions include leading the large, multicenter AGO ROBOT study, which provided critical insights into the clinical characteristics, surgical staging, and prognosis of BOT. His work demonstrated that incomplete surgical staging is a negative prognostic factor for BOT patients, and he has explored age-dependent differences in outcomes and the value of serum CA125 in diagnosis. In the realm of ovarian cancer, du Bois has advanced the understanding of HRD as a real-world biomarker, evaluating its prevalence and therapeutic implications through next-generation sequencing in over 500 tumor samples. His research has garnered significant attention, with his most cited paper on age-dependent BOT outcomes accumulating 75 citations. Additionally, he has investigated quality of life and sexual function in BOT survivors, as well as the implementation of robot-assisted surgery across different BMI groups, showcasing his commitment to both clinical outcomes and patient-centered care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary14 citations · 2015
- 5
- 6
- 7